Inflammations has been increasingly identified as a major risk factor across many disease areas particularly in Cardiovascular, immunological and auto-immune diseases. We have extensive experience in Phase 2 to Phase 3 clinical trials including major outcome studies involving anti-inflammatory drugs. Our deep understanding of key inflammatory biomarkers and safety parameters helps in efficient clinical trials designs.

Immunology experience:

We have extensive experience in Statistics, Data management, Clinical Operations and Field Monitoring from Phase 2 to Post marketing studies. Our experience include:

  • Inflammatory bowel disease
  • Psoriatic arthritis
  • Osteoarthritis
  • Gout
  • Psoriasis